Coagulation factor V (Arg506→Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting

Thrombosis and Haemostasis

Volumn 80, Issue 2, 1998, Pages 220-224

  Moor, Elisabeth ^a   Silveira, Angela ^a   Van't Hooft, Ferdinand ^a   Tornvall, Per ^a   Blombäck, Margareta ^a   Wiman, Björn ^a   Rydén, Lars ^a   Hamsten, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; FIBRIN; PROTHROMBIN; THROMBIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; ELECTIVE SURGERY; FIBRIN FORMATION; GENE MUTATION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT; THROMBIN TIME; VEIN OCCLUSION;

EID: 0031825899     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615176     Document Type: Article

References (33)

1. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
2. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
3. Griffin JH, Evatt BL, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-93.
4. Koster T, Rosendaal FR, de Ronde F, Brïet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
5. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-21.
6. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Progr Cardiovasc Dis 1991; 34: 45-68.
7. Verstraete M, Brown BG, Chesebro JH, Ekeström S, Harker LA, Henderson AH, Jewitt DE, Oliver MF, Sleight P. Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion. Eur Heart J 1986; 7: 4-13.
8. Pfisterer M, Jockers G, Regenass S et al. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet 1989; 2: 1-7.
9. Vermylen C, de Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerisation time (FPT test). Clin Chim Acta 1963; 8: 418-24.
10. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44
11. Silveira A, Green F, Karpe F, Blombäck M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism. Thromb Haemost 1994; 72: 734-9.
12. Pelzer H, Schwarz A, Heimburger N. Determination of human Thrombin-Antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-6.
13. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-9.
14. Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988; 68: 437-43.
15. Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. Clin Chem 1986; 32; 3: 482-5.
16. Ødegaard OR, Try K, Andersson TR. Protein C: An automated activity assay. Haemostasis 1987; 17: 109-13.
17. Wiman B, Rånby M. Determination of soluble fibrin in plasma by rapid and quantitative spectrophotometric assay. Thromb Haemost 1986;55: 189-93.
18. Carlson K. Lipoprotein fractionation. J Clin Path 1973; 5 (suppl. 26): 32-7.
19. Arnesen H, Semb G, Hol R, Karlsen H. Fibrinolytic capacity after venous stasis in patients undergoing aorto-coronary by-pass surgery. Relation to shunt occlusion. Scand J Haematol 1983; 30 (suppl 39): 43-6.
20. Eritsland J, Gjonnes G, Sandset PM, Seljeflot I, Arnesen H. Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 1995; 79: 223-6.
21. Rosén S, Johansson K, Lindberg K, Dahlbäck B (for the APC resistance group). Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-60.
22. Freyburger G, Bilhou-Nabera C, Dief S, Javorschi S, Labrouche S, Lerebeller MJ, Boisseau MR. Technical and biological conditions influencing the functional APC resistance test. Thromb Haemost 1996; 75: 460-5.
23. Alhenc-Gelas M, Gandrille S, Aubry ML, Emmerich J, Fiessinger JN, Aiach M. Unexplained thrombosis and factor V Leiden mutation. Lancet 1994; 344: 555-6.
24. 506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-4.
25. Martinelli I, Bottasso B, Duca F, Faioni E, Mannuccio Mannucci P. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996; 75: 703-5.
26. Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-3.
27. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 995; 345: 526-7.
28. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
29. 506Gln factor V mutation (factor V Leiden) in patients with ischemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-60.
30. Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K. Evidence against heterozygous coagulation factor V 1691 G→A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. Mol Med 1995;73: 521-4.
31. Demarmels Biasiutti F, Merlo C, Furlan M, Sulzer I, Binder BR, Lämmle B. No association of APC resistance with myocardial infarction. Blood Coag Fibrinol 1995; 6: 456-9.
32. Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996; 239: 221-6.
33. 506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996; 75: 701-2.